Division of Cardiology, Children's Hospital of Michigan, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan (Drs Sarno, Misra, Siddeek, Kheiwa, and Kobayashi); Division of Pediatric Cardiology, East Carolina University Brody School of Medicine, Greenville, North Carolina (Dr Sarno); Division of Pediatric Cardiology, University of Minnesota, Minneapolis, Minnesota (Dr Siddeek); and Division of Cardiology, Adult Congenital Heart Disease Program, Loma Linda Medical Center, Loma Linda, California (Dr Kheiwa).
J Cardiopulm Rehabil Prev. 2020 Jan;40(1):E1-E4. doi: 10.1097/HCR.0000000000000482.
Cardiac rehabilitation (CR) effectively decreases morbidity and mortality in adults after cardiovascular events. Cardiac rehabilitation has been underutilized for patients with congenital heart disease (CHD). The primary objective was to evaluate the inclusion of adolescents and adults with CHD in a CR program by analyzing data from our single-center CR program. The secondary objectives were to evaluate the efficacy and safety of CR as well as referral barriers.
This was a retrospective study of patients aged ≥15 yr who were referred to regional CR centers. Data on efficacy and safety were collected.
Over a 4-yr period, 36 patients were referred to 23 regional centers: 23 patients completed CR, 12 are currently enrolled or in the referral process, and 1 died before initiation. The median age was 22 yr (range: 15-55). The primary indication was post-surgical (61%), followed by chronic heart failure (30%), and post-transplant (9%). After CR, metabolic equivalent tasks increased by 1.6 (P < .001), maximal heart rate increased by 13 beats/min (P = .026), exercise time increased by 1.35 min (P = .047), and treadmill speed increased by 0.7 mph (P = .007). There were no serious adverse events. All patients who completed CR remain alive at a median follow-up of 17 mo (range: 5-45). Common barriers to CR included accessibility, social circumstances, and cost for phase III CR.
In our cohort, CR was effective and safe for adolescents and adults with CHD.
心脏康复(CR)可有效降低心血管事件后成年人的发病率和死亡率。先天性心脏病(CHD)患者对心脏康复的利用率较低。主要目的是通过分析我们单一中心 CR 计划的数据来评估将青少年和成年人纳入 CR 计划的情况。次要目的是评估 CR 的疗效和安全性以及转诊障碍。
这是一项对≥15 岁的被转诊至区域 CR 中心的患者进行的回顾性研究。收集了疗效和安全性数据。
在 4 年期间,有 36 名患者被转诊至 23 个区域中心:23 名患者完成了 CR,12 名正在入组或在转诊过程中,1 名在开始前死亡。中位年龄为 22 岁(范围:15-55 岁)。主要适应证为手术后(61%),其次为慢性心力衰竭(30%)和移植后(9%)。CR 后,代谢当量任务增加了 1.6(P<0.001),最大心率增加了 13 次/分钟(P=0.026),运动时间增加了 1.35 分钟(P=0.047),跑步机速度增加了 0.7 英里/小时(P=0.007)。没有发生严重不良事件。所有完成 CR 的患者在中位随访 17 个月(范围:5-45 个月)时仍存活。CR 的常见障碍包括可及性、社会情况和第三阶段 CR 的费用。
在我们的队列中,CR 对 CHD 青少年和成年人是有效且安全的。